Effects of cannabis use on human brain structure in psychosis: A systematic review combining in vivo structural neuroimaging and post mortem studies

Current Pharmaceutical Design

Volumn 18, Issue 32, 2012, Pages 5070-5080

  Rapp, Charlotte ^a   Bugra, Hilal ^a   Riecher Rössler, Anita ^a   Tamagni, Corinne ^a   Borgwardt, Stefan ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

At risk mental state (ARMS); Cannabis; Magnetic resonance imaging (MRI); Neuroimaging; Post mortem; Psychosis

Indexed keywords

CANNABINOID 1 RECEPTOR;

AUTOPSY; BRAIN ATROPHY; BRAIN REGION; CANNABIS USE; CEREBELLUM; CINGULATE GYRUS; EXPOSURE; GENETIC RISK; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; MENTAL PATIENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; BRAIN; CADAVER; CANNABIS ADDICTION; PATHOLOGY;

BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MARIJUANA ABUSE; POSTMORTEM CHANGES; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 84875494735     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802884861     Document Type: Review

References (88)

1. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66: 442-51
2. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764-74
3. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010; 13: 421-32
4. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66: 95-105
5. Winton-Brown TT, Allen P, Bhattacharyya S, et al. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology 2011; 36: 1340-8
6. Borgwardt SJ, Allen P, Bhattacharyya S, et al. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 2008; 64: 966-73
7. Bhattacharyya S, Crippa JA, Allen P, et al. Induction of psychosis by {delta}9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 2012; 69: 27-36
8. Martin-Santos R, Fagundo AB, Crippa JA, et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychological Medicine 2010; 40: 383-398
9. Quickfall J, Crockford D. Brain neuroimaging in cannabis use: A review. J Neuropsychiatry Clinical Neurosci 2006; 18: 318-32
10. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yücel M. Structural MRI Findings in Long-Term Cannabis Users: What Do We Know? Substance Use & Misuse 2010; 45: 1787-808
11. Lawston J, Borella A, Robinson JK, Whitaker-Azmitia PM. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Research 2000; 877: 407-10
12. Chan GCK, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of Delta(9)-tetrahydrocannabinol. Journal of Neuroscience 1998; 18: 5322-32
13. Bossong MG, Niesink RJM. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology 2010; 92: 370-85
14. Konings M, Henquet C, Maharajh HD, Hutchinson G, Van Os J. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatrica Scandinavica 2008; 118: 209-13
15. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 2002; 156: 319-27
16. Casadio P, Fernandes C, Murray RM, Di Forti M. Cannabis use in young people: The risk for schizophrenia. Neuroscience and Biobehavioral Reviews 2011; 35: 1779-1787
17. Barnett JH, Werners U, Secher SM, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. British Journal of Psychiatry 2007; 190: 515-20
18. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: A meta-analysis of voxel-based morphometry studies. American Journal of Psychiatry 2005; 162: 2233-45
19. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia - A systematic and quantitative review of volumetric magnetic resonance imaging studies. British Journal of Psychiatry 1998; 172: 110-20
20. Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 2000; 157: 16-25
21. Fusar-Poli P, Borgwardt S, Crescini A, et al. Neuroanatomy of Vulnerability to Psychosis: A Voxel-Based Meta-Analysis. Neurosci Biobehav Rev 2011; 35: 1175-85
22. Fusar-Poli P, Radua J, McGuire P, Borgwardt S. Neuroanatomical Maps of Psychosis Onset: Voxel-wise Meta-Analysis of Antipsychotic-Naive VBM Studies. Schizophr Bull 2011: Epub
23. Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Moller HJ, Riecher-Rossler A. Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study. Schizophr Bull 2011
24. Mechelli A, Riecher-Rossler A, Meisenzahl EM, et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry 2011; 68: 489-95
25. Smieskova R, Fusar-Poli P, Allen P, et al. Neuroimaging predictors of transition to psychosis - A systematic review and meta-analysis. Neurosci Biobehavioural Rev 2010; 34: 1207-22
26. Smieskova R, Fusar-Poli P, Aston J, Simon A, Bendfeldt K, Lenz C, Stieglitz RD, McGuire P, Riecher-Rössler A, Borgwardt SJ. Insular volume abnormalities associated with different transition probabilities to psychosis Psychological Medicine, Available on CJO 2011 doi: 10.1017/S0033291711002716
27. Smieskova R, Fusar-Poli P, Allen P, et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?--a systematic review. Current pharmaceutical design 2009; 15: 2535-49
28. Borgwardt SJ, Radue EW, Gotz K, et al. Radiological findings in individuals at high risk of psychosis. Journal of neurology, neurosurgery, and psychiatry 2006; 77: 229-33
29. Borgwardt SJ, Riecher-Rossler A, Dazzan P, et al. Regional gray matter volume abnormalities in the at risk mental state. Biological psychiatry 2007; 61: 1148-56
30. Haller S, Borgwardt SJ, Schindler C, Aston J, Radue EW, Riecher-Rossler A. Can cortical thickness asymmetry analysis contribute to detection of at-risk mental state and first-episode psychosis? A pilot study. Radiology 2009; 250: 212-21
31. Borgwardt SJ, McGuire PK, Aston J, et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry Suppl 2007; 51: s69-75
32. Borgwardt SJ, McGuire PK, Aston J, et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res 2008; 106: 108-14
33. Velakoulis D, Wood S, Wong M, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63: 139-49
34. Borgwardt SJ, McGuire P, Fusar-Poli P, Radue EW, Riecher-Rossler A. Anterior cingulate pathology in the prodromal stage of schizophrenia. Neuroimage 2008; 39: 553-4
35. Borgwardt SJ, Picchioni MM, Ettinger U, Toulopoulou T, Murray R, McGuire PK. Regional gray matter volume in monozygotic twins concordant and discordant for schizophrenia. Biol Psychiatry 2010; 67: 956-64
36. Borgwardt S, McGuire P, Fusar-Poli P. Gray matters!--mapping the transition to psychosis. Schizophrenia Research 2011; 133: 63-7
37. Fusar-Poli P, McGuire P, Borgwardt S. Mapping prodromal psychosis: A critical review of neuroimaging studies. Eur Psychiatry 2011
38. DeLisi LE. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Current Opinion in Psychiatry 2008; 21: 140-150
39. Stone JM, Bhattacharyya S, Barker G, McGuire PK. Substance use and regional grey matter volume in individuals at high risk of psychosis. European Neuropsychopharmacology 2011; 21: S63-64
40. Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J, Group. Reduced Cortical Thickness as an Outcome of Differential Sensitivity to Environmental Risks in Schizophrenia. Biological Psychiatry 2011; 69: 487-94
41. Welch KA, McIntosh AM, Job DE, et al. The Impact of Substance Use on Brain Structure in People at High Risk of Developing Schizophrenia. Schizophrenia Bulletin 2011; 37: 1066-76
42. Welch KA, Stanfield AC, McIntosh AM, et al. Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia. Br J Psychiatry 2011
43. Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008; 165: 490-6
44. Rais M, van Haren NEM, Cahn W, et al. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. European Neuropsychopharmacology 2010; 20: 855-65
45. Cahn W, Hulshoff Pol HE, Caspers E, van Haren NEM, Schnack HG, Kahn RS. Cannabis and brain morphology in recent-onset schizophrenia. Schizophrenia Research 2004; 67: 305-7
46. Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Research-Neuroimaging 2010; 181: 51-6
47. Peters BD, de Haan L, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH. Recent-Onset Schizophrenia and Adolescent Cannabis Use: MRI Evidence for Structural Hyperconnectivity? Psychopharmacology Bulletin 2009; 42: 75-88
48. Deng C, Han M, Huang XF. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neuroscience Bulletin 2007; 23: 341-7
49. Zavitsanou K, Garrick T, Huang XF. Selective antagonist [H-3]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004; 28: 355-60
50. Callcut RA, Branson RD. How to Read a Review Paper. Respiratory Care 2009; 54: 1379-85
51. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surgery 2010; 8: 336-41
52. Solowij N, Yucel M, Respondek C, et al. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychological Medicine 2011; 41: 2349-59
53. Cohen M, Rasser PE, Peck G, et al. Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. The International Journal of Neuropsychopharmacology 2011; FirstView: 1-11
54. Szeszko PR, Robinson DG, Sevy S, et al. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. British Journal of Psychiatry 2007; 190: 230-236
55. Bangalore SS, Prasad KMR, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia - A region of interest, voxel based morphometric study. Schizophrenia Research 2008; 99: 1-6
56. Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophrenia Research 2011; 128: 66-75
57. James A, Hough M, James S, et al. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophrenia Research 2011; 128: 91-7
58. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: The comprehensive assessment of at-risk mental states. Australian and New Zealand Journal of Psychiatry 2005; 39: 964-71
59. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [H-3]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103: 9-15
60. Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Archives of General Psychiatry 2008; 65: 772-84
61. Ashton CH. Pharmacology and effects of cannabis: a brief review. British Journal of Psychiatry 2001; 178: 101-6
62. Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American Journal of Psychiatry 2008; 165: 490-6
63. Welch KA, McIntosh A, Moorhead W, et al. The Impact of Substance Use on Brain Structure in People at Genetically High Risk of Schizophrenia. Schizophrenia Bulletin 2011; 37: 182-2
64. Mathalon DH, Pfefferbaum A, Lim KO, Rosenbloom MJ, Sullivan EV. Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Archives of General Psychiatry 2003; 60: 245-52
65. Berman S, O'Neill J, Fears S, Bartzokis G, London ED. Abuse of Amphetamines and Structural Abnormalities in the Brain. Addiction Reviews 2008 2008; 1141: 195-220
66. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry 2001; 50: 71-83
67. Dubertret C, Bidard I, Ades J, Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophrenia Research 2006; 86: 284-90
68. Jockers-Scherubl MC, Matthies U, Danker-Hopfe H, Lang UE, Mahlberg R, Hellweg R. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. Journal of Psychopharmacology 2003; 17: 439-45
69. Fusar-Poli P, Stone JM, Broome MR, et al. Thalamic Glutamate Levels as a Predictor of Cortical Response During Executive Functioning in Subjects at High Risk for Psychosis. Arch Gen Psychiatry 2011; 68: 881-90
70. Stone JM, Howes OD, Egerton A, et al. Altered Relationship Between Hippocampal Glutamate Levels and Striatal Dopamine Function in Subjects at Ultra High Risk of Psychosis. Biological Psychiatry 2010; 68: 599-602
71. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. European Psychiatry 2005; 20: 349-53
72. Lieberman J, Chakos M, Wu HW, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry 2001; 49: 487-99
73. Robins LN, Wing J, Wittchen HU, et al. The Composite International Diagnostic Interview - an Epidemiologic Instrument Suitable for Use in Conjunction with Different Diagnostic Systems and in Different Cultures. Archives of General Psychiatry 1988; 45: 1069-77
74. Ho BC, Flaum M, Hubbard W, Arndt S, Andreasen NC. Validity of symptom assessment in psychotic disorders: information variance across different sources of history. Schizophrenia Research 2004; 68: 299-307
75. Darke S, Ward J, Hall W, Heather N, Wodak A. The Opiate Treatment Index (OTI) Researcher's Manual. National Drug and Alcohol Research Centre: Sydney 1991
76. Mancini-Marie A, Potvin S, Fahim C, Beauregard M, Mensour B, Stip E. Neural correlates of the affect regulation model in schizophrenia patients with substance use history: A functional magnetic resonance imaging study. Journal of Clinical Psychiatry 2006; 67: 342-50
77. Leweke FM, Giuffrida A, Koethe D, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophrenia Research 2007; 94: 29-36
78. Safont G, Corripio I, Escarti MJ, et al. Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study. Schizophrenia Research 2011; 129: 169-71
79. Loberg EMM, Jorgensen HA, Nygard M, Berle JO, Hugdahl K. Cannabis Use and Brain Functioning in Schizophrenia: An Fmri Study. Schizophrenia Bulletin 2011; 37: 144-5
80. Potvin S, Mancini-Maeie A, Fahim C, Mensour B, Stip E. Processing of social emotion in patients with schizophrenia and substance use disorder: An fMRI study. Social Neuroscience 2007; 2: 106-16
81. Parkar SR, Ramanathan S, Nair N, et al. Are the effects of cannabis dependence on glucose metabolism similar to schizophrenia? An FDG PET understanding. Indian J Psychiatry 2011; 53: 13-20
82. Newell KA, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research 2006; 172: 556-60
83. Dalton VS, Long LE, Weickert CS, Zavitsanou K. Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex. Neuropsychopharmacology 2011; 36: 1620-30
84. Potvin S, Mancini-Marie A, Fahim C, et al. Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: A voxel-based morphometry study. Psychiatry Research-Neuroimaging 2007; 154: 275-9
85. Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P. Comorbid substance abuse and brain morphology in recent-onset psychosis. European Archives of Psychiatry and Clinical Neuroscience 2009; 259: 28-36
86. Ebdrup BH, Glenthoj B, Rasmussen H, et al. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. Journal of Psychiatry & Neuroscience 2010; 35: 95-104
87. Koethe D, Llenos IC, Dulay JR, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transmission 2007; 114: 1055-63
88. Wobrock T, Hasan A, Malchow B, et al. Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. Psychopharmacology 2010; 208: 353-363